Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study - - Phase 1b dose expansion has commenced; plan...
-
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
-
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
-
Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with...
-
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader...